Recon: FDA reviewers flag eye risks with GSK’s blood cancer therapy; FDA ends import screening exemption for low-value goods

• FDA staff flags eye safety risks for GSK's blood cancer drug (Reuters)
• The end of animal testing? Transitioning to models is promising — but no silver bullet (STAT)
• Weight-loss drug use in kids surged after doctors' recommendation (Axios)
• The Trump administration disbanded a newborn screening panel. Advocates now face a harder path (Endpoints)
• FDA employees let go in April receive final termination notices (Endpoints)
• HHS Formally Lays Off Employees Following Supreme Court Ruling (Bloomberg)
• Judge rejects AbbVie’s fight against Missouri 340B contract pharmacy law (Endpoints)
• FDA chief calls for lower user fees as negotiations begin for eighth round of PDUFA (Endpoints)
• Consumer Groups Have A ‘Radical Transparency’ List For US FDA’s PDUFA VIII (Pink Sheet)
• FDA to screen all imports, exemptions for low-value shipments revoked (Reuters)

• After Phase 3 obesity success, Hengrui plans China approval filing for Kailera-partnered drug (Endpoints)
• Global childhood vaccination shows slight improvement but challenges remain (Reuters)
• Sino Biopharmaceutical to acquire LaNova Medicines for up to $951 million (Reuters)
• Anthem Biosciences' $395 million IPO fully subscribed as investors bet on Indian pharma (Reuters)
• ViiV expands license to allow generic HIV treatment production for low-income countries (Reuters)
• Kailera touts late-stage win for weight-loss drug in China (Reuters)
• Indira IVF Said to Revive India IPO That May Raise $408 Million (Bloomberg)
• Vaccination Rates Lag in Europe as Measles Cases Rise, WHO Says (Bloomberg)

• SpaceX Plans Starship Program for In-Orbit Drug Research (Bloomberg)
• An AstraZeneca Exit Wouldn’t Doom London (Bloomberg)
• How Hims Became the King of Knockoff Weight-Loss Drugs (Bloomberg)
• Bayer's Kerendia wins FDA label expansion to treat 2 types of heart failure (Fierce Pharma)

• Quest to offer Fujirebio’s FDA-cleared Alzheimer’s blood test (MedTech Dive)
• Zimmer agrees to distribute Getinge products to expand ASC offering (MedTech Dive)
• Zimmer to buy robotics firm Monogram for about $177M (MedTech Dive)
• Waters’ Purchase Of BD Biosciences & Dx Brings Growth Potential Alongside Trade-Offs (MedTech Insight)

• FDA approves natural blue color, urges accelerated phaseout of synthetic red dye (Food Dive)
• US ice cream makers commit to artificial dye phase-out by 2028 (Food Dive)

• Study finds no evidence aluminum salts in vaccines are tied to higher risk of asthma, other childhood diseases (STAT)
• After long saga, 23andMe's deal with Anne Wojcicki's nonprofit finally closes (Endpoints)
• West Virginia abortion ban upheld over drugmaker's challenge (Reuters)
• Ex-Pfizer Doctor Tells Congress He Didn’t Delay Covid Shot Data (Bloomberg)
• Stealth Stake Sales Helped UnitedHealth Beat Wall Street Targets (Bloomberg)